证券代码：000920 证券简称：沃顿科技 公告编号：2025-035 沃顿科技股份有限公司 关于参加 2025 年投资者集体接待日暨 2024 年度业绩说明会 并征集问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沃顿科技股份有限公司（以下简称"公司"）已分别披露《2024 年年度报告》和《2025 年一季度报告》，为便于广大投资者更深入 全面地了解公司情况，公司将参加由贵州证监局指导、贵州证券业协 会与深圳市全景网络有限公司联合举办的 2025 年贵州辖区上市公司 投资者集体接待日暨 2024 年度业绩说明会并征集相关问题。本次活 动具体安排如下： 欢迎投资者积极参与问题征集，同时公司诚挚邀请广大投资者在 业绩说明会召开时间与公司出席的董事、高管进行交流。 特此公告。 一、业绩说明会的安排 召开时间：2025 年 5 月 12 日（星期一）15:40-17:40。 召开方式：网络远程方式。 出席人员：公司董事长蔡志奇先生，独立董事王立明先生，董事 会秘书赵峰先生，副总经理、财务总监兼总法律顾问郑巍先生。 参与方式：投资者可登录 http://r ...

Group 1: Financial Performance - The company's gross profit margin improved due to ongoing production line upgrades and enhanced production efficiency [1] - Supply chain management optimization and domestic material procurement significantly contributed to cost reduction and efficiency gains [1] Group 2: Capacity and Market Demand - Current production capacity can be further enhanced based on equipment upgrades, with infrastructure supporting additional capacity expansion [1] - The company can dynamically adapt its production scale to meet market demand increases, ensuring it does not become a bottleneck for growth [1] Group 3: Competitive Advantages - The company has achieved international advanced levels in product technology, tailored solutions to local application scenarios, and maintains a comprehensive service network [2] - Strong understanding of domestic industry policies and market characteristics allows for precise market trend identification and rapid product iteration [2] Group 4: Subsidiary Performance - The subsidiary, Daziran, leverages unique material properties to create differentiated competitive advantages and has built a stable customer base [3] - Daziran's introduction of a full-home customization brand enhances customer value and brand influence, aiming for stable revenue in 2024 despite challenging operating conditions [3]

Financial Performance - The company reported a basic earnings per share of 0.0940 yuan for Q1 2025, representing a 30.37% increase compared to 0.0721 yuan in Q1 2024 [1] - Net profit for Q1 2025 was 0.44 billion yuan, up 29.41% from 0.34 billion yuan in Q1 2024 [1] - Operating revenue reached 3.63 billion yuan in Q1 2025, an increase of 8.36% from 3.35 billion yuan in Q1 2024 [1] - The return on equity (ROE) improved to 2.34% in Q1 2025, compared to 1.88% in Q1 2024, marking a 24.47% increase [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 21,810.07 million shares, accounting for 51.68% of the circulating shares, with a decrease of 615,100 shares from the previous period [1] - The largest shareholder, CRRC Industry Investment Co., Ltd., holds 18,935.22 million shares, representing 44.87% of the total share capital, with no change in holdings [2] - The second largest shareholder, CRRC Guiyang Vehicle Co., Ltd., holds 1,192.42 million shares, also unchanged [2] - Notably, Xu Jiangfeng exited the top ten shareholders, while Gu Anqi entered as a new shareholder with 142.84 million shares [2] Dividend Policy - The company has decided not to distribute dividends or allocate bonus shares in this period [3]

Financial Performance - The company's revenue for Q1 2025 was CNY 363,362,796.94, representing an increase of 8.43% compared to CNY 335,125,944.26 in the same period last year[5] - Net profit attributable to shareholders was CNY 44,447,842.51, a growth of 30.35% from CNY 34,098,070.09 year-on-year[5] - Basic earnings per share increased by 30.37% to CNY 0.0940 from CNY 0.0721 in the same quarter last year[5] - Net profit for the current period was ¥46,385,870.80, representing a 30% increase from ¥35,663,332.22 in the previous period[20] - The operating profit increased to ¥54,509,922.96, compared to ¥36,100,324.28, marking a growth of 51%[20] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -22,418,587.67, a decline of 132.45% compared to CNY 69,076,078.69 in the previous year[5] - The net cash flow from operating activities was negative at -¥22,418,587.67, a significant decline from ¥69,076,078.69 in the previous period[23] - Cash and cash equivalents at the end of the period were CNY 752,499,241.16, down from CNY 770,355,576.78[16] - Cash and cash equivalents at the end of the period totaled ¥741,083,523.59, compared to ¥669,116,037.35 at the end of the previous period, indicating an increase of 10.7%[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,738,811,513.71, down 1.60% from CNY 2,783,211,613.47 at the end of the previous year[5] - Current assets totaled CNY 1,499,561,004.41, down from CNY 1,512,094,178.84[16] - Non-current assets decreased to CNY 1,239,250,509.30 from CNY 1,271,117,434.63[17] - Total liabilities were CNY 656,194,594.91, down from CNY 731,381,622.70[17] - The total equity attributable to the parent company was CNY 1,898,671,777.09, an increase from CNY 1,869,971,449.76[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,129, with no preferred shareholders[11] - The largest shareholder, CRRC Industry Investment Co., Ltd., holds 45.42% of the shares, totaling 214,662,759 shares[11] Other Income and Expenses - The company reported a significant increase in other income, which rose by 138.84% to CNY 4,273,905.43 from CNY 1,789,430.44 year-on-year[9] - The company reported a tax expense of ¥8,305,369.87, significantly higher than ¥654,043.25 in the previous period, indicating increased profitability[20] - Other comprehensive income after tax was negative at -¥17,365,293.94, contrasting with a positive figure of ¥4,855,321.88 in the previous period[20] Operational Changes - The company appointed Jin Yan as the new General Manager and Wu Zongce as the Deputy General Manager and Chief Engineer[14] - The company will hold its first temporary shareholders' meeting and employee representative meeting on February 25, 2025, to elect members of the eighth board of directors and supervisory board[13] Operating Costs - Total operating costs amounted to ¥312,857,056.75, up from ¥300,417,764.60, reflecting a rise of 4.8%[19] - The company experienced a cash outflow from investing activities of -¥3,802,551.39, an improvement from -¥6,467,770.40 in the previous period[23]

证券代码：000920 证券简称：沃顿科技 公告编号：2025-033 （一）召开时间 1、现场会议召开时间：2025 年 4 月 23 日 15:30。 2、网络投票时间： 沃顿科技股份有限公司 2024 年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （一）本次股东会未出现否决提案的情形。 （二）本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开的情况 （1）通过交易系统进行网络投票的时间为 2025 年 4 月 23 日 9:15 至 9:25，9:30 至 11:30 和 13:00 至 15:00。 （2）通过互联网投票系统进行网络投票的时间为 2025 年 4 月 23 日 9:15 至 15:00。 （二）召开地点：贵州省贵阳市贵阳国家高新技术产业开发区黎 阳大道 1518 号 102 五楼会议室。 （三）召开方式：现场表决与网络投票相结合。 （四）召集人：公司董事会。 （五）主持人：董事长蔡志奇先生。 （六）公司董事、监事、高级管理人员、国浩律师（贵阳）事务 所见证律师出席了会议。 （七）会议的召集、召开 ...

国浩律师（贵阳）事务所 法律意见书 国浩律师（贵阳）事务所 关于沃顿科技股份有限公司2024年度股东会的 法律意见书 国浩所（2025）法意字第 0385 号 国浩律师（贵阳）事务所（以下简称"本所"）接受沃顿科技 股份有限公司（以下简称"沃顿科技"或"公司"）的委托，指派 宋诗阳、潘志成律师出席沃顿科技 2024 年度股东会（简称"本次 股东会"），就本次股东会有关法律事宜进行现场查验，并出具本 法律意见书。 本所律师根据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司股东会规则》等法律、法规和规范性文件以及《沃 顿科技股份有限公司章程》（简称"《公司章程》"），对本次股东会 的召集、召开程序，出席会议人员、召集人的资格，会议的表决 程序及表决结果等有关法律事宜进行了查验，现出具法律意见如 下： 一、本次股东会的召集与召开程序 沃顿科技董事会已于 2025 年 3 月 28 日在《证券时报》和"巨 潮资讯网"上刊登了《沃顿科技股份有限公司关于召开 2024 年度 股东会的通知》，在法定期限内公告了有关本次股东会的召开时 间、地点、方式、审议事项、出席会议人员的资格、会议登记办 法等相关事宜，依法 ...

Group 1 - The core business of Walton Technology includes core membrane business, membrane separation engineering, and plant fiber business [1] - Membrane products are categorized into ultrafiltration membranes, nanofiltration membranes, and reverse osmosis membranes, with significant price differences between household and industrial membranes [1] - In 2024, the revenue share of household and industrial membranes is expected to be approximately 37% [1] - The growth in gross margin is attributed to increased production scale, production line upgrades, process improvements, and enhanced supply chain management [1] - The production base has reserved expansion space, enabling rapid initiation of new production line construction [1] - Nearly 30% of membrane product revenue comes from exports, with a small proportion of products exported to the United States, and overseas market growth is expected to exceed 20% in 2024 [1] - The membrane separation engineering business aims to explore broader application scenarios, transitioning the company into a comprehensive service provider [1] - The plant fiber business is developing steadily, consolidating its leading position in the palm fiber industry [1] Group 2 - Shanghai Dapu Asset Management Co., Ltd. was established in January 2012 and has a team with rich research and investment experience from well-known domestic securities research institutions and investment firms [2] - The investment team focuses on investment and research in the Chinese securities market, maintaining an active management and steady progress investment style [2] - The company adheres to the principles of standardized operation and professional investment, with a complete corporate governance structure that reflects sufficient incentives, investment independence, professional division of labor, and sustainable operation [2]

Group 1: Xianle Health - The company emphasizes its advantages in pharmaceutical DNA, innovation-driven approach, global supply chain, and comprehensive dosage forms, positioning itself as a leader in global nutrition and health solutions [1] - Xianle Health is facing dual opportunities from the evergreen market and new consumption market, with four competitive advantages: scale, ecosystem, internationalization, and technology [1] - The company expects to achieve a revenue of 4.211 billion yuan in 2024, representing a year-on-year growth of 17.56%, and plans to distribute a cash dividend of 6.5 yuan per 10 shares (tax included) [1] Group 2: Wharton Technology - Wharton Technology's business includes core membrane products, membrane separation engineering, and plant fiber business, with membrane products categorized into ultrafiltration, nanofiltration, and reverse osmosis membranes [2] - The revenue share of household membranes and industrial membranes is approximately 37%, with gross margin growth driven by increased production scale, production line upgrades, process improvements, and enhanced supply chain management [2] - The company anticipates over 20% growth in overseas markets in 2024, with nearly 30% of membrane product revenue coming from exports [2] Group 3: Borui Pharmaceutical - Borui Pharmaceutical has made progress in mylin target research, with BGM1812 showing potential for fat reduction with minimal muscle loss, and plans to submit IND applications in China and the U.S. [3] - The company believes that the mylin and dual-target combination has international competitiveness and plans to advance clinical trials in the U.S. [3] - Over half of the R&D investment is directed towards metabolic directions, with the remainder focused on high-barrier generics and innovative drugs, primarily in respiratory and inhalation formulations [3]

Group 1: Business Overview - The company's operations are divided into three main segments: core membrane business, membrane separation engineering, and plant fiber business [1] - Core membrane business includes research, manufacturing, and sales of separation membrane products such as reverse osmosis, nanofiltration, and ultrafiltration membranes, with applications in over 130 countries [1] - The membrane separation engineering business focuses on promoting and applying membrane separation technology, providing comprehensive services and project operation maintenance [1] Group 2: Membrane Product Classification - Membrane products are classified based on two dimensions: separation precision and functionality, categorized into ultrafiltration (UF), nanofiltration (NF), and reverse osmosis (RO) membranes [2] - Further segmentation includes household membranes for domestic use and industrial membranes for large-scale production [2] Group 3: Revenue and Pricing - There is a significant price difference between household and industrial membranes, with household membranes benefiting from standardized designs and economies of scale [3] - The revenue ratio for household membranes to industrial membranes is approximately 3:7 for 2024 [4] Group 4: Profitability and Capacity - The gross margin of the membrane business has shown stable growth due to increased production scale, production line upgrades, and improved supply chain management [5] - The company has reserved capacity for expansion and can quickly initiate new production lines, ensuring capacity will not be a bottleneck for growth [6] Group 5: Export and Market Expansion - Approximately 30% of the company's membrane product revenue comes from exports, with a small proportion exported to the United States [6] - The overseas market is expected to grow by over 20% in 2024 [6] Group 6: Future Development and Strategy - The membrane separation engineering business aims to explore broader application scenarios and enhance core competitiveness through upstream and downstream collaboration [8] - The company plans to undertake more projects with higher process solution requirements and expand into new downstream application areas while managing payment risks [8] Group 7: Plant Fiber Business - The plant fiber business is developing steadily, focusing on strengthening sales channels, brand image, and optimizing product structure to maintain a leading position in the coconut fiber industry [8]

证券代码：000920 证券简称：沃顿科技 公告编号：2025-032 沃顿科技股份有限公司 关于召开 2024 年度股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 沃顿科技股份有限公司（以下简称"公司"）将于 2025 年 4 月 23 日召开 公司 2024 年度股东会，具体内容详见刊载于"巨潮资讯网"（网址： www.cninfo.com.cn）和《证券时报》的《关于召开公司 2024 年度股东会的 通知》（公告编号：2025-028），现就此次股东会的有关事项提示公告如下： 一、召开会议基本情况 （一）股东会届次：2024 年度股东会。 （五）召开时间 1、现场会议召开时间：2025 年 4 月 23 日 15:30。 2、网络投票时间： （1）通过交易系统进行网络投票的时间为 2025 年 4 月 23 日 9:15 至 9:25，9:30 至 11:30 和 13:00 至 15:00； 第 1 页 （2）通过互联网投票系统进行网络投票的时间为2025年4月23日9:15 至 15:00。 （六）股权登记日：2025 年 4 月 ...